COVID-19

Since the initial identification of SARS-CoV-2 as causative agent of COVID-19 more than 33.900.000 cases (as of 1st October 2020) have been registered worldwide. Although huge efforts are made to combat the outbreak, still no drugs or vaccines are available.

To support the scientific community we updated our resources on current research:

Cytokine Release Syndrome Cytokine Release Syndrome — Click to discover
In most cases, a SARS-CoV-2 infection is cleared at this stage by the recruited immune cells and the immune response is downregulated. However, in patients developing severe COVID-19, inflammatory processes do not subside.
SARS-CoV-2 Life Cycle: Stages and Inhibition Targets SARS-CoV-2 Life Cycle: Stages and Inhibition Targets — Click to discover
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by club-like spikes on the surface, and a unique replication strategy. In the following the replication cycle of SARS-Cov-2 is explained together with possible inhibitors and their respective targets.
COVID-19 COVID-19 — Click to discover
Since the initial identification of the novel coronavirus SARS-CoV-2 as causative agent of COVID-19 almost 25.700.000 infections (as of 18 August 2020) have been registered worldwide. Thanks to global research efforts, a picture of the virus biology and its effect in the human host is emerging. We offer a wide variety of high quality products for COVID-19 research.
SARS-CoV-2 Interactome SARS-CoV-2 Interactome — Click to discover
Recently, a systematic analysis of interactions of the 26 SARS-CoV-2 proteins with host cell proteins has highlighted the significance of the virus’ ability to modulate specific pathways to propagate. Many of these key host interaction partners are targets for drugs already approved for other diseases, or in clinical or pre-clinical stage. This knowledge opens the door to novel approaches to counter SARS-CoV-2 infections and improve outcomes of COVID-19 and associated pathologies.
Cytokine Release Syndrome

NEW: SARS-CoV-2 IgG Multiplex ELISA
High performance COVID-19 antibody testing. Five antigens printed in the same well. Increased diagnostic performances: 99.6% specificity, 95.9% sensitivity.

See Product Details

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *